<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084951</url>
  </required_header>
  <id_info>
    <org_study_id>SQZ-PBMC-HPV-101</org_study_id>
    <nct_id>NCT04084951</nct_id>
  </id_info>
  <brief_title>Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SQZ Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SQZ Biotechnologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic
      effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in
      combination with atezolizumab in HLA-A*02+ patients with recurrent, locally advanced or
      metastatic human papillomavirus strain 16 positive (HPV16+) solid tumors. The study includes
      patients with anal, rectal, cervical, head and neck, penile, vulvar, or vaginal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Semi-sequential enrollment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0</measure>
    <time_frame>approximately 10 months</time_frame>
    <description>For SQZ-PBMC-HPV as a single agent and in combination with atezolizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>approximately 6 weeks</time_frame>
    <description>MTD of SQZ-PBMC-HPV as a single agent and in combination with atezolizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose (RP2D)</measure>
    <time_frame>approximately 10 months</time_frame>
    <description>RP2D of SQZ-PBMC-HPV as a single agent and in combination with atezolizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Tumor assessments using RECIST 1.1 of SQZ PBMC-HPV monotherapy and in combination with atezolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manufacturing feasibility</measure>
    <time_frame>1 year</time_frame>
    <description>number of vials</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with development of endogenous immune responses via ELISPOT in CD8 T cells</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Immunogenic effects on peripheral blood cells of SQZ-PBMC-HPV as a single agent and in combination with atezolizumab</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with change in blood cytokine levels</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>SQZ-PBMC-HPV as a single agent and in combination with atezolizumab</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adult Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose escalation of SQZ-PBMC-HPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the monotherapy escalation cohorts, SQZ-PBMC-HPV is administered every 3 weeks for up to a year as a low and a high cell dose. In addition, a second high dose cell cohort will test the impact of a double-prime regimen where SQZ-PBMC-HPV is administered on two consecutive days followed by doses every 3 weeks for a maximum of a year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation of SQZ-PBMC-HPV + atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the combination escalation cohorts, SQZ-PBMC-HPV in combination with atezolizumab is given for up to a year at intervals of 3 weeks as a low and a high cell dose. In addition, a second high dose cell dose cohort will test the impact of a double-prime regimen of SQZ-PBMC-HPV given in combination with atezolizumab. Participants may continue to receive atezolizumab study drug every 3 weeks for a maximum of 1 year or until discontinuation criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SQZ-PBMC-HPV</intervention_name>
    <description>antigen presenting cell therapy; therapeutic vaccine consisting of autologous peripheral blood mononuclear cells (PBMCs) presenting immunogenic epitopes of the E6 and E7 proteins of HPV16</description>
    <arm_group_label>Dose escalation of SQZ-PBMC-HPV</arm_group_label>
    <arm_group_label>Dose escalation of SQZ-PBMC-HPV + atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>programmed cell death ligand 1 (PD-L1) blocking antibody</description>
    <arm_group_label>Dose escalation of SQZ-PBMC-HPV + atezolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients â‰¥18 years of age who are HLA-A*02

          -  Histologically confirmed incurable or metastatic solid tumors that are HPV16+

          -  Cancer must have progressed after at least 1 available standard therapy for incurable
             disease, or the patient is intolerant to or refuses standard therapy(ies) or has a
             tumor for which no standard therapy(ies) exist

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1

          -  At least 1 measurable lesion according to RECIST 1.1

          -  Patients must agree to venous access for the leukapheresis and be willing to have a
             central line inserted if venous access is an issue.

        Exclusion Criteria:

          -  Treatment with anticancer therapy, including investigational therapy, within 2 weeks
             prior to leukapheresis. For prior therapies with a half-life longer than 3 days,
             discontinuation of the therapy must have occurred at least 28 days prior to
             leukapheresis

          -  Known active hepatitis B or hepatitis C, or active mycobacterium tuberculosis
             infection

          -  History of any Grade 4 immune-related AE (irAE) from prior immunotherapy

          -  Significant acute or chronic illness

          -  Major surgery within 2 weeks of leukapheresis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin Greenberg</last_name>
    <phone>978 407 6007</phone>
    <email>PBMC-HPV-101@sqzbiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer</last_name>
      <phone>480-323-1364</phone>
      <email>clinicaltrials@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Michael S Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Cancer Pavillion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Nguyen</last_name>
      <phone>720-848-4394</phone>
      <email>ana.nguyen@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Antonio Jimeno, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Roesgen</last_name>
      <phone>913-945-8679</phone>
      <email>jroesgen@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joaquina Baranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DFCI Clinical Trials Hotline</last_name>
      <phone>877-338-7425</phone>
    </contact>
    <investigator>
      <last_name>Ursula Matulonis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Office</last_name>
      <phone>503-215-2614</phone>
      <email>canrsrchstudies@providence.org</email>
    </contact>
    <investigator>
      <last_name>Matthew H Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Information Program</last_name>
      <phone>800-811-8480</phone>
      <email>CIP@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Cathy Eng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abha Adat</last_name>
      <phone>713-745-4297</phone>
      <email>aadat@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Filip Janku, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 1, 2019</study_first_submitted>
  <study_first_submitted_qc>September 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>locally advanced</keyword>
  <keyword>cancer</keyword>
  <keyword>cervical</keyword>
  <keyword>head and neck</keyword>
  <keyword>anal</keyword>
  <keyword>penile</keyword>
  <keyword>SQZ-PBMC-HPV</keyword>
  <keyword>atezolizumab</keyword>
  <keyword>HPV16</keyword>
  <keyword>APC</keyword>
  <keyword>cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

